Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Rhea-AI Summary

Sight Sciences, a leader in eyecare technology, announced participation in the Bank of America Healthcare Conference scheduled for May 12, 2022, at 9:20 am PT. The event will showcase the company's innovative solutions aimed at enhancing patient care, including the OMNI® Surgical System and TearCare® System, which target prevalent eye diseases. Interested investors can access the live and archived webcast on the company’s Investors page on their website. This initiative underscores the company’s commitment to transforming eyecare.

MENLO PARK, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

Sight Sciences’ management is scheduled to present Thursday, May 12, 2022, at 9:20am PT. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.

Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

FAQ

When is Sight Sciences presenting at the Bank of America Healthcare Conference?

Sight Sciences will present on May 12, 2022, at 9:20 am PT.

How can I access the webcast for Sight Sciences' conference presentation?

You can access the live and archived webcast on the Investors section of Sight Sciences' website.

What products does Sight Sciences focus on in eyecare?

Sight Sciences focuses on the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease.

What is the purpose of the OMNI® Surgical System by Sight Sciences?

The OMNI® Surgical System is designed to reduce intraocular pressure in patients with primary open-angle glaucoma.

What is the TearCare® System used for?

The TearCare® System provides localized heat therapy for treating evaporative dry eye disease caused by meibomian gland dysfunction.